Table 3.

Change on clinical symptom measures between baseline and treatment week 12. ^{^}

	Olanzapine (N = 40)	Quetiapine (N = 31)	Risperidone (N = 33)	Placebo (N = 47)
ADCS-ADL total score, mean change (SD)	−6.1 (8.2) *	−1.0 (7.7)	−1.1 (8.8)	0.5 (8.4)
ADAS-Cog total score, mean change (SD)	0.7 (6.1)	0.8 (6.9)	1.7 (5.2)	1.3 (5.7)
MMSE score, mean change (SD)	−0.1 (3.7)	−0.8 (3.8)	−0.8 (3.2)	−0.7 (2.7)
ADRQL total score, mean change (SD)	6.4 (12.6)	6.7 (11.7)	2.1 (12.1)	4.1 (15.8)
Caregiver Activity Survey, mean change in hours (SD)	0.2 (4.8)	−0.7 (4.3)	−1.1 (4.7)	−0.6 (4.1)

^{^}Mean change score for those patients taking the assigned phase 1 medication at week 12 are shown.

For ADCS-ADL, MMSE, and ADRQL, a change score >0 reflects clinical improvement. For ADAS-Cog and Caregiver Activity Survey, a change score <0 reflects clinical improvement.

^*p<.001, pairwise comparison vs. placebo; ANCOVA model with adjustment for pooled site and baseline score.